Document is current
Any future updates will be listed below
-
Authors
Hahn, Andrew W. https://orcid.org/0000-0002-4153-205X
Tidwell, Rebecca S. https://orcid.org/0000-0003-3041-8582
Pilie, Patrick G.
Yu, Yao
Liu, Jingjing
Surasi, Devaki Shilpa
Titus, Mark
Zhang, Jianhua
Venkatesh, Neha
Panaretakis, Theocharis
Gregg, Justin R.
Zurita, Amado J. https://orcid.org/0000-0002-3805-7307
Siddiqui, Bilal A.
Corn, Paul G.
Subudhi, Sumit K. https://orcid.org/0000-0001-5208-7732
Msaouel, Pavlos https://orcid.org/0000-0001-6505-8308
Koutroumpakis, Efstratios https://orcid.org/0000-0002-6757-6480
Huff, Chad D.
Aparicio, Ana https://orcid.org/0000-0003-0900-0923
McQuade, Jennifer L.
Frigo, Daniel E. https://orcid.org/0000-0002-0713-471X
Logothetis, Christopher J. https://orcid.org/0000-0002-6365-1711
-
Funding
Funding for this research was provided by:
Conquer Cancer Foundation (FP00011981)
Prostate Cancer Foundation (21YOUN33)
U.S. Department of Defense (W81XWH2210117)
- License Information
-
More Information
Article History
Received: 27 March 2024
Revised: 28 June 2024
Accepted: 8 July 2024
First Online: 17 July 2024
Competing interests
: AWH reports advisory board consulting for Johnson & Johnson Innovative Medicine, Intellisphere, Exelixis, and Eisai; honoraria from Medscape and Binaytara Foundation; travel support from DAVA Oncology, and institutional research funding from Bayer and Eisai. PGP has received honoraria for service on scientific advisory board for Janssen and AstraZeneca. JRG is a consultant and advisory board member for Bayer. BAS reports advisory board consulting to Merck, travel support from Merck, and institutional research funding from Regeneron. PM has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics, Bristol Myers Squibb, and Exelixis; consulting for Axiom Healthcare Strategies; non-branded educational programs supported by DAVA Oncology, Exelixis and Pfizer; and research funding for clinical trials from Takeda, Bristol Myers Squibb, Mirati Therapeutics, Gateway for Cancer Research, and the University of Texas MD Anderson Cancer Center. JLM reports honorari from Merck, Bristol-Myers Squibb, and Novartis. CJL reports honoraria from Bayer, Amgen, Novartis, Boehringer Ingelheim, Merck Sharp & Dohme, and Exelixis; and institutional research funding from Janssen, ORIC Pharmaceuticals, Novartis, and Aragon Pharmaceuticals. DEF has received research funding from GTx, Inc, and has a familial relationship with Biocity Biopharmaceuticals, Hummingbird Bioscience, Bellicum Pharmaceuticals, Maia Biotechnology, Alms Therapeutics, Hinova Pharmaceuticals, and Barricade Therapeutics.
: This research involving human subjects, human material, and human data is in accordance with the Declaration of Helsinki. Informed consent was obtained from subjects. The research reported here was approved by The University of Texas MDACC Institutional Review Board (PA16-0736 2014-0386, LAB02-152).
